https://www.selleckchem.com/pr....oducts/thal-sns-032.
surgery service. These patients have a higher risk for mid-term mortality. The optimal antithrombotic regimen after transcatheter aortic valve replacement remains unclear. In this randomized open-label study, low-risk patients undergoing transfemoral transcatheter aortic valve replacement at 7 centers in the United States were randomized 11 to low-dose aspirin or warfarin plus low-dose aspirin for 30 days. Patients who could not be randomized were enrolled in a separate registry. Computed tomography or transesophageal echocardiogra
Like
Comment
Share
